Skip to main content
SpringerLink
Log in

Mortality as an Outcome in Sepsis Trials

  • Published:
Sepsis

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Petros AJ, Marshall JC, van Saene HKF. Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 1995;345:369–371.

    Google Scholar 

  2. Sackett DL. The competing objectives of randomized trials. N Engl J Med 1980;303:1059–1060.

    Google Scholar 

  3. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301: 1410–1412.

    Google Scholar 

  4. Bernard GR. Sepsis trials: intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med 1995;152:4–10.

    Google Scholar 

  5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction:ISIS-2. Lancet 1988; August 13:349–360.

    Google Scholar 

  6. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–685.

    Google Scholar 

  7. Garber BG, Hebert PC, Yelle JD, Hodder RV, McGowan J. Adult respiratory distress syndrome: a systematic overview of incidence and risk factors. Crit Care Med 1996;24:687–695.

    Google Scholar 

  8. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989;17:389–393.

    Google Scholar 

  9. Pocock SJ, Armitage P, Galton DAG. The size of cancer clinical trials: an international survey. UICC Tech Rep Ser 1978;36:5–34.

    Google Scholar 

  10. Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: survey of 71 “negative” trials. N Engl J Med 1978;299: 690–694.

    Google Scholar 

  11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient I. Introduction and design. Br J Cancer 1976;34:585–612.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Career Scientist of the Ontario Ministry of Health Critical Care Program and, The Clinical Epidemiology Unit, University of Ottawa, Ontario, Canada

    Paul C. Hébert

Authors
  1. Paul C. Hébert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hébert, P.C. Mortality as an Outcome in Sepsis Trials. Sepsis 1, 35–40 (1997). https://doi.org/10.1023/A:1009759217413

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009759217413

Keywords

Search

Navigation